Floatz logo

Rivaroxaban

Hemorrhage

Assistance Publique - Hôpitaux de ParisSmall moleculePhase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Hemorrhage cohort.

Asset / SponsorPhaseRating
Tranexamic Acid
Daniel Nishijima, MD, MAS
Phase 4BBB
Plavix
Chonnam National University Hospital
Phase 4BB
CARVEDILOL
Shanghai Zhongshan Hospital
Phase 4BB
PROPRANOLOL
Shanghai Zhongshan Hospital
Phase 4BB
Acetylsalicylic Acid
Chonnam National University Hospital
Phase 4BB

View all 20 →

Same molecule, other indications

Rivaroxaban is also rated in:

atrial fibrillationDormant
BBB
Indicative ·
79 / 100
View asset →
hemorrhagic diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
thrombotic diseaseDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →